What is the 13F Pro Quality Score for BEAM?

13F Pro ranks Beam Therapeutics Inc. (BEAM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BEAM's current score at https://13fpro.ai/research/BEAM (free sign-up required for the full ranking).

Which hedge funds own the most BEAM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BEAM include FMR, ARK Investment Management, FARALLON CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BEAM as soon as new 13F filings post.

Where does 13F Pro source BEAM data?

All Beam Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Beam Therapeutics Inc. files with the SEC under CIK 1745999. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BEAM in?

Beam Therapeutics Inc. (BEAM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BEAM research updated on 13F Pro?

BEAM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Beam Therapeutics Inc.(BEAM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1745999 BEAM stock profile & AI dashboard →

13F Pro Quality Score

12.1/100

Rank #2,785 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

13.7/100

Profitability

3.0/100

Balance Sheet

8.0/100

Earnings Quality

30.0/100

Free Cash Flow

2.7/100

Institutional Flow

72.0/100

Revenue Scale

12.5/100

Dilution Risk

4.0/100

BEAM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Beam Therapeutics Inc. (BEAM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BEAM at 12.1/100 on a 32-signal composite quality model, placing it at rank #2,785 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (2.7) and profitability (3.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Beam Therapeutics Inc. reports quarterly revenue of $31.7M, net income of $-94.3M, free cash flow of $-130.7M. Top institutional holders of BEAM by reported 13-F value include FMR, ARK Investment Management, FARALLON CAPITAL MANAGEMENT, based on the most recent SEC filings. BEAM trades on the Nasdaq exchange and files with the SEC under CIK 1745999. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BEAM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Beam Therapeutics Inc. directly from SEC EDGAR. Beam Therapeutics Inc.'s 13F Pro composite quality score has ranged between 6 and 52 since 2021, currently 12.1 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Beam Therapeutics Inc.

Quirks, history, and lore behind BEAM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · clinical-stage · listed on Nasdaq · headquartered in Cambridge, Massachusetts.
2
The Numbers
Generates minimal product revenue — like most clinical-stage biotechs — and has a market cap in the low billions, sustained largely by partnerships and equity raises.
3
The History
Founded around 2017 by pioneers in the gene-editing field, it went public in 2020 and quickly became one of the most-watched names in next-generation genomic medicine.
4
The Secret
While rivals cut DNA, this company's platform specializes in base editing — chemically rewriting a single DNA letter without making a double-strand break, potentially a safer approach.
5
The Lore
Its co-founders include David Liu, the Broad Institute scientist who invented base editing itself — making this one of the rare cases where the inventor of the core technology also launched the company built around it.
6
The Giveaway
The company's very name is a metaphor for its science: just as a beam of light is precise and targeted, it aims to fix genetic disease one nucleotide base at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$31.7M

Net Income

Q1 2026

$-94.3M

Free Cash Flow

Q1 2026

$-130.7M

ROIC

Q1 2026

-8.5%

D/E Ratio

Q1 2026

0.09

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+120.0% YoY

$139.7MFY 2025

FY21 $51.8MFY22 $60.9MFY24 $63.5MFY25 $139.7M

Net Income

+78.8% YoY

$-80.0MFY 2025

FY21 $-370.7MFY22 $-289.1MFY24 $-376.7MFY25 $-80.0M

Operating Income

+7.7% YoY

$-383.7MFY 2025

FY21 $-392.5MFY22 $-338.5MFY24 $-415.6MFY25 $-383.7M

EPS (Diluted)

+82.3% YoY

$-0.81FY 2025

FY21 $-5.77FY22 $-4.13FY24 $-4.58FY25 $-0.81

Total Assets

+34.2% YoY

$1.48BFY 2025

FY21 $1.47BFY22 $1.34BFY24 $1.10BFY25 $1.48B

Op. Cash Flow

+0.6% YoY

$-345.1MFY 2025

FY21 $-66.3MFY22 $22.5MFY24 $-347.2MFY25 $-345.1M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$139.7M +120.0%	$63.5M +4.3%	$60.9M +17.5%	$51.8M +215916.7%	$24.0K +33.3%	$18.0K
Net Income	$-80.0M +78.8%	$-376.7M -30.3%	$-289.1M +22.0%	$-370.7M -90.5%	$-194.6M -148.4%	$-78.3M
Operating Income	$-383.7M +7.7%	$-415.6M -22.8%	$-338.5M +13.8%	$-392.5M -195.6%	$-132.8M -76.7%	$-75.2M
EPS (Diluted)	$-0.81 +82.3%	$-4.58 -10.9%	$-4.13 +28.4%	$-5.77 -37.7%	$-4.19 -33.7%	$-3.13
Total Assets	$1.48B +34.2%	$1.10B -17.7%	$1.34B -9.0%	$1.47B +226.4%	$451.7M +189.4%	$156.1M
Operating Cash Flow	$-345.1M +0.6%	$-347.2M -1641.5%	$22.5M +134.0%	$-66.3M +30.8%	$-95.7M -33.0%	$-72.0M

Get alerted when BEAM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Beam Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BEAM

FMR LLC
$296.7M12,452,199 sh
ARK Investment Management LLC
$289.1M12,133,433 sh
FARALLON CAPITAL MANAGEMENT LLC
$241.5M10,134,696 sh
BlackRock, Inc.
$202.3M8,487,569 sh
STATE STREET CORP
$135.8M5,699,265 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$108.9M4,570,797 sh
ARCH Venture Management, LLC
$108.2M4,540,132 sh
VANGUARD CAPITAL MANAGEMENT LLC
$104.3M4,377,374 sh
Nikko Asset Management Americas, Inc.
$91.2M3,825,585 sh
Sumitomo Mitsui Trust Holdings, Inc.
$91.2M3,825,585 sh

Fund	Value	Shares
FMR LLC	$296.7M	12,452,199
ARK Investment Management LLC	$289.1M	12,133,433
FARALLON CAPITAL MANAGEMENT LLC	$241.5M	10,134,696
BlackRock, Inc.	$202.3M	8,487,569
STATE STREET CORP	$135.8M	5,699,265
VANGUARD PORTFOLIO MANAGEMENT LLC	$108.9M	4,570,797
ARCH Venture Management, LLC	$108.2M	4,540,132
VANGUARD CAPITAL MANAGEMENT LLC	$104.3M	4,377,374
Nikko Asset Management Americas, Inc.	$91.2M	3,825,585
Sumitomo Mitsui Trust Holdings, Inc.	$91.2M	3,825,585

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BEAM on your watchlist

Track score changes the day Beam Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BEAM a good stock to buy?

13F Pro's AI-powered analysis of Beam Therapeutics Inc. (BEAM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BEAM are available on the BEAM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BEAM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BEAM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Beam Therapeutics Inc.'s investment landscape.